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Abstract 
BACKGROUND: Actinic keratoses (AKs) are precancerous epidermal lesions induced by chronic exposure to 
ultraviolet light. Several topical and surgical treatments are available. For field cancerization, photodynamic 
therapy (PDT) is a very effective noninvasive treatment with excellent outcome and cosmesis. The management 
of treatment-associated adverse events, however, is crucial to achieve the treatment aims and to ensure patients 
adherence to PDT. 
CASE REPORT: We report on adverse events and their management related to PDT. We conducted literature 
research on PUBMED (R). Also, we present a case of an uncommon adverse event-PDT-induced rosacea flare-
up on scalp and eyes. The patient was treated successfully by submicrobial slow-release doxycycline orally. 
Conclusions: PDT is an excellent treatment option for multiple AKs such as in bald scalp field cancerization. The 
management of adverse events during and after PDT is an essential part of a successful treatment plan. 
 
 
 
 
 
 
 
 
Introduction 
 
Actinic keratoses (AKs) are common 
dysplastic intraepidermal lesions induced by chronic 
exposure to ultraviolet radiation (UVR). The 
prevalence of AKs in the United States has been 
estimated at nearly 40 million in 2004. AKs have the 
ability to progress to cutaneous squamous cell 
carcinoma (SCC) rate a yearly rate of 0.6% in the 
elderly population [1]. Multiple AKs often develop on 
the bald scalp in patients with an outdoor profession 
such as farmers, construction workers, or sailors. 
Such a situation has been described as field 
cancerization since the affected area is at higher risk 
to develop cutaneous squamous cell carcinomas 
(SCC) [2]. Recently, the AK area and severity index 
(AKASI) has been developed as a new quantitative 
tool for assessing AK severity on the head and to 
monitor outcomes of different treatments [3]. 
For the treatment of AKs, various 
pharmacological, surgical and phototherapeutic 
approaches are available. One of the highly preferred 
methods to treat field cancerization is photodynamic 
therapy (PDT) [4], [5]. 
PDT is a non-invasive method that combines 
a photosensitizer that accumulated in preneoplastic 
and neoplastic epidermal keratinocytes with 
subsequent irradiation. Protoporphyrin IX (PpIX) is the 
photosensitizer most commonly used in 
dermatological PDT. Soluble precursors to PpIX such 
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as 5-aminolevulinic acid (ALA) or methyl-
aminolevulinate (MAL) are used in topical ointments. 
These compounds are absorbed by the skin and 
enzymatically converted into PpIX within the 
keratinocytes. In contrast to normal keratinocytes, 
preneoplastic and neoplastic cells accumulate more 
PpIX more rapidly than normal cells because their 
heme biosynthesis is elevated. The most effective 
way to activate intracellular PpIX is an irradiation with 
635 nm [6]. By irradiation, the photosensitizer 
becomes activated and leads to oxidative stress in 
mitochondria and membranes, resulting in cell death 
[7]. 
 
Case Report 
 
A 70-year-old Caucasian male patient present 
with a field cancerization with multiple actinic 
keratoses (AKs) on the forehead and scalp (Figure 1). 
His medical history was remarkable for facial and 
scalp rosacea, but the disease was in remission. 
In the past, actinic keratoses were treated 
topically with diclofenac sodium 3% in hyaluronic acid 
2.5% gel and 0.015% ingenol mebutate gel. However, 
this did not result in complete remissions but showed 
a rather rapid relapse. Therefore, photodynamic 
treatment (PDT) was suggested. 
 
Figure 1: Field cancerization of the bald scalp 
 
He underwent a single PDT. The session 
started with roughing of the actinically damaged skin 
with a mono-filamentous fibre pad (Debrisoft®, 
Lohmann & Rauscher GmbH & Co. KG, Neuwied, 
Germany). The area was disinfected with Octenisept® 
solution (SCHÜLKE & MAYR GmbH, Norderstedt, 
Germany). After that, a gel containing 78 mg 5-
aminolaevulinic acid nanoemulsion (Ameluz®, 
Biofrontera AG, Leverkusen, Germany) was applied. 
The area was covered by the aluminum foil for 3 
hours. Before irradiation, the gel residues were 
removed with a wet gauze compress. Irradiation was 
performed with a narrow-band red light with a peak 
wavelength of 635 nm and a total light intensity of 37 
J/cm
2 
(BF-RHODO LED®, Biofrontera). During PDT, 
skin surface was treated by cooled air and an ice-
spray. After PDT, skincare with a cream containing an 
extract of Mahonia aquifolium (Beliox® cream, 
Biofrontera AG) for at least two weeks was 
recommended. 
Immediately after the procedure, moderate 
erythema was noted. The following days, he 
developed the usual inflammatory reaction in the 
treated area, which improved after topical treatment 
with moisturiser. 
After 2 weeks, however, he presented with a 
severe flare-up of preexistent rosacea with multiple 
papulopustules on the scalp (red scalp syndrome) and 
ocular involvement with blepharon-conjunctivitis 
(Figure 2). He received oral low-dose doxycycline 
(Oraycea 40 mg retard capsules 1 x d) with rapid 
improvement within 10 days. 
 
Figure 2: Rosacea eruption on the scalp after successful PDT. No 
actinic keratoses can be seen but erythematous papules 
 
Literature review on adverse events of 
 dermatological PDT 
The major drawback of PDT is the strong pain 
experienced during the irradiation with 635 nm light 
that can sometimes become even intolerable for 
patients, requiring interruption or termination of the 
process [4], [5]. Reactive oxygen species, transient 
receptor potential channels and inflammatory 
reactions are mediators in pain. This type of pain does 
not respond to oral pharmacological pain killers. 
Topical anaesthesia is of limited value. In a 
comparative trial, the scalp nerve block was more 
effective than intravenous (IV) analgesia with 
piritramide 7.5 mg IV plus oral metamizole in 
combination with cold-air analgesia, and cold-air 
analgesia alone [8].  
An alternative to classical red-light irradiation 
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is day-light PDT. The efficacy is slightly lower in 
particular in case of thicker AKs. On the other hand, 
low-irradiance light sources (such as variable pulsed 
light and daylight PDT) are currently the best 
analgesic option [9]. 
Other treatment-emergent adverse events are 
erythema, bullous reactions, transient oedema, and 
oozing. These cutaneous adverse events are 
experienced by 100% of treated patients in variable 
grades of severity. Sun-protection after PDT and 
moisturisers for skincare are highly recommended. 
Usually, these adverse events disappear within 2 
weeks after PDT [10], [11]. 
 
 
Discussion 
 
PDT is a versatile treatment option in 
dermatology to improve symptoms of extrinsic ageing, 
including actinic keratoses but also acne and rosacea 
[12],[13],[14]. Adverse events are temporary and 
include pain sensations and localised inflammatory 
reactions. Here we report a rather uncommon adverse 
event after successful PDT – a rosacea flare-up. 
During the treatment of field cancerization, 
rosacea is a possible adverse event. In a trial with 
topical ALA-PDT and red light, 70 J/cm
2
 for mild and 
moderate AKs rosacea occurred in 6.6% of cases 
[15]. In a series of 30 patients with field cancerization 
treated by 5-aminolaevulinic acid nano-emulsion and 
narrow-band red light, no rosacea was noted [12]. 
Our patient presented with a combination of 
papulopustular eruptions on his scalp, suggesting a 
red scalp syndrome and ocular rosacea. Red scalp 
syndrome is part of the rosacea spectrum and 
responds very well to oral low-dose doxycycline [16], 
[17]. Systemic treatment is also warranted in the case 
of ocular rosacea involvement [18]. 
An alternative for the treatment of actinic 
keratoses and rosacea would be the use of combined 
Q-switched KTP 532 nm and Nd: YAG 1064 nm laser 
[19], combined intense pulse light and Q-switched 
KTP 532 nm, or Q-switched KTP 532 nm laser alone 
[20]. All of these methods work on precancerous 
lesions. They also target telangiectasia (KTP) and 
erythema (Nd: YAG and IPL). However, none of these 
is efficient for papulopustular rosacea. 
Rosacea is known to be aggravated by 
several endogenous and exogenous factors. Heat 
activates both TRPV1 and TRPV2 (transient 
receptor potential vanilloid), which are involved in 
rosacea pathogenesis. Inflammasome (NALP3) and 
TLR-2 are induced by sun-light exposure in rosacea. 
Last not least, cosmetics have been shown to induce 
TRPA1 (transient receptor potential ankyrin 1) [19]. 
Although not studied in detail, various pathogenetic 
pathways might have been involved in this rare 
adverse effect of PDT – red scalp and blepharon-
conjuctivitis. 
In conclusion, PDT is a versatile noninvasive 
method in dermatology. The major medial indication is 
the treatment of multiple AKs and field cancerization. 
Adverse events are common but of a temporary 
nature. While pain and inflammatory reactions are 
noted in almost all patients, rosacea is a rather 
uncommon unwanted side effect. Treatment is as in 
idiopathic rosacea. 
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